The IBN SINA Pharmaceutical Industry PLC (DSE:IBNSINA)
297.20
-0.70 (-0.23%)
At close: Nov 4, 2026
DSE:IBNSINA Balance Sheet
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 297.31 | 314.9 | 365.23 | 232.23 | 342.61 |
Short-Term Investments | - | 22.5 | 166.79 | - | - |
Cash & Short-Term Investments | 297.31 | 337.4 | 532.02 | 232.23 | 342.61 |
Cash Growth | -11.88% | -36.58% | 129.09% | -32.22% | 21.82% |
Accounts Receivable | 189.77 | 189.86 | 195.83 | 96.1 | 43.61 |
Other Receivables | - | 6.19 | 6.69 | 11.03 | 10.22 |
Receivables | 189.77 | 196.05 | 202.51 | 107.13 | 53.83 |
Inventory | 1,972 | 1,808 | 1,585 | 1,157 | 1,008 |
Other Current Assets | 843.2 | 503.71 | 300.44 | 340.44 | 232.54 |
Total Current Assets | 3,303 | 2,845 | 2,620 | 1,836 | 1,637 |
Property, Plant & Equipment | 7,433 | 4,621 | 3,826 | 3,103 | 2,596 |
Long-Term Investments | - | 46.66 | 54.17 | 57.22 | 56.11 |
Other Long-Term Assets | 75.1 | 33.72 | 9.05 | 8.8 | 21.66 |
Total Assets | 10,810 | 7,547 | 6,509 | 5,006 | 4,310 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 1,307 | 396.18 | 260.3 | 282.31 | 166.18 |
Accrued Expenses | - | 246.61 | 249.51 | 218.04 | 97.59 |
Short-Term Debt | 2,636 | 953.68 | 1,243 | 512.14 | 534.29 |
Current Portion of Long-Term Debt | 172.53 | 119.45 | 62.3 | 72.21 | 70.18 |
Current Portion of Leases | - | 23.8 | 25.54 | 22.41 | 22.06 |
Current Income Taxes Payable | 719.78 | 495.25 | 284.58 | 212.06 | 165.56 |
Other Current Liabilities | 28.04 | 241.6 | 193.32 | 142.3 | 68.17 |
Total Current Liabilities | 4,864 | 2,477 | 2,318 | 1,461 | 1,124 |
Long-Term Debt | 1,197 | 974.71 | 530.49 | 330.09 | 368.01 |
Long-Term Leases | - | - | 24.8 | 51.34 | 74.75 |
Pension & Post-Retirement Benefits | 0.51 | 0.99 | 1.19 | 1.01 | 0.73 |
Long-Term Deferred Tax Liabilities | 93.03 | 96.46 | 101.18 | 105.81 | 117.72 |
Other Long-Term Liabilities | -0 | 0 | 0 | -0 | - |
Total Liabilities | 6,155 | 3,549 | 2,976 | 1,950 | 1,685 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 312.44 | 312.44 | 312.44 | 312.44 | 312.44 |
Retained Earnings | 4,225 | 3,630 | 3,194 | 2,711 | 2,293 |
Comprehensive Income & Other | -20.51 | -15.54 | -8.61 | -2.27 | -0.69 |
Total Common Equity | 4,517 | 3,927 | 3,497 | 3,021 | 2,604 |
Minority Interest | 139.24 | 70.95 | 35.88 | 35.05 | 20.66 |
Shareholders' Equity | 4,656 | 3,998 | 3,533 | 3,056 | 2,625 |
Total Liabilities & Equity | 10,810 | 7,547 | 6,509 | 5,006 | 4,310 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 4,006 | 2,072 | 1,886 | 988.19 | 1,069 |
Net Cash (Debt) | -3,709 | -1,717 | -1,328 | -723.75 | -695.57 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -118.71 | -54.94 | -42.52 | -23.16 | -22.26 |
Filing Date Shares Outstanding | 31.24 | 31.24 | 31.24 | 31.24 | 31.24 |
Total Common Shares Outstanding | 31.24 | 31.24 | 31.24 | 31.24 | 31.24 |
Working Capital | -1,561 | 368.68 | 302.22 | 374.96 | 512.52 |
Book Value Per Share | 144.56 | 125.69 | 111.94 | 96.68 | 83.36 |
Tangible Book Value | 4,517 | 3,927 | 3,497 | 3,021 | 2,604 |
Tangible Book Value Per Share | 144.56 | 125.69 | 111.94 | 96.68 | 83.36 |
Construction In Progress | - | 1,932 | 1,139 | 572.47 | 144.25 |